Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Sleep Wake Disorders 1Radiation Injuries 1Pinealoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Meningioma 1Medulloblastoma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Fatigue 1Ependymoma 1Depression 1Craniopharyngioma 1Cognition Disorders 1Chronic Pain 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anxiety Disorders 1

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Donepezil × Clear all
NCT01466270 2021-10-20

Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction

Wake Forest University Health Sciences

Phase 2 Completed
62 enrolled 12 charts
Breast

Anxiety Disorders, Breast Neoplasms, Cognition Disorders, Depression, Fatigue, Sleep Wake Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡